← Leaderboards
Scott Michael Schuetze
University Of Michigan At Ann Arbor
$8,096,162
Attributed
$9,566,762
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,109,243 · 7
By mechanism
P50$10,034,113 · 3
P30$5,133,415 · 2
UG1$2,941,201 · 1
M01$514 · 1
Top collaborators
- Jonathan A Fletcher3 shared
- Zora Djuric2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Gregory Peter Kalemkerian$1,137,226
- Craig J Galban$12,293,457
- Eric R. Fearon$27,558,344
- Phillip Scott$5,205,337
- Devin L Brown$28,775,275
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchProgramsTranslational ResearchClinical TrialsReportingInstitutionUniversitiesMichiganResearch PersonnelMonitorEnsureResourcesClinicClinical Trials Support UnitCancer Clinical TrialProtocols DocumentationMedical SchoolsResponseSafetyTumorInfrastructureTranslationsClinical ProtocolsClinical Data
Grant awards (25)
Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment$1,890,694
P50 · FY2025 · CA · contact PI
Early Phase Clinical Cancer Prevention Consortium$1,449,424
UG1 · FY2025 · CA · contact PI
Clinical Protocol and Data Management$775,624
P30 · FY2025 · CA · contact PI
Core B: Clinical Trials Core$245,662
P50 · FY2025 · CA · contact PI
Core A: Administrative Core$221,733
P50 · FY2025 · CA · contact PI
Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment$2,094,748
P50 · FY2024 · CA · contact PI
Early Phase Clinical Cancer Prevention Consortium$1,491,777
UG1 · FY2024 · CA · contact PI
Clinical Protocol and Data Management$746,042
P30 · FY2024 · CA · contact PI
Core A: Administrative Core$286,470
P50 · FY2024 · CA · contact PI
Core B: Clinical Trials Core$235,835
P50 · FY2024 · CA · contact PI
Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment$2,274,206
P50 · FY2023 · CA · contact PI
Clinical Protocol and Data Management$762,308
P30 · FY2023 · CA · contact PI
Core A: Administrative Core$251,546
P50 · FY2023 · CA · contact PI
Core B: Clinical Trials Core$250,386
P50 · FY2023 · CA · contact PI
Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment$2,282,833
P50 · FY2022 · CA · contact PI
Clinical Protocol and Data Management$555,864
P30 · FY2022 · CA · contact PI
Clinical Protocol and Data Management$566,220
P30 · FY2021 · CA · contact PI
Clinical Protocol and Data Management$566,220
P30 · FY2020 · CA · contact PI
Clinical Protocol and Data Management$566,218
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$565,918
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$9,970
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$8,971
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$7,661
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$2,399
P30 · FY2018 · CA · contact PI
ALDOSTERONE RECEPTOR BLOCKADE BY SPIRONOLACTONE ON LV DIASTOLIC FUNCTION$514
M01 · FY2005 · RR